EMA Application withdrawn: Repaglinide Sun (repaglinide) — Sun Pharmaceutical Industries B.V.

View source ↗

Summary

The EMA withdrew the application for Repaglinide Sun for type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Repaglinide SUN (repaglinide)

Snippet

Status: Application withdrawn. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Sun Pharmaceutical Industries B.V.. Decision date: 26/04/2010